Articles tagged with: Revlimid
News»

A new study published in the journal Leukemia determined that when treated with Revlimid (lenalidomide) and dexamethasone (Decadron), relapsed and refractory myeloma patients with genetic risk factors experience lower response rates and shorter progression-free and overall survival durations.
Researchers also discovered that prior treatment with thalidomide (Thalomid) was associated with a decreased progression-free and overall survival.
Multiple myeloma patients with the chromosomal abnormalities del(13), t(4;14) or del(17p) are associated with a poorer prognosis in response to traditional chemotherapy. However, new drug and treatment options have the potential to overcome …
News»

The year 2009 brought a lot of new and exciting advancements in the field of multiple myeloma. Over the course of 2009, The Myeloma Beacon covered more than 100 important myeloma-related studies.
To highlight the most important of these studies, the Myeloma Beacon surveyed leading physicians and researchers in the field. These physicians and researchers were asked to name the three peer reviewed journal articles published in 2009 and the three conference abstracts from 2009 that have the most important findings or implications relating to multiple myeloma.
The top three journal …
News»

Patients who do not respond at least partially to treatment with Revlimid (lenalidomide) or thalidomide (Thalomid) prior to a stem cell transplant may have significantly shorter survival times, according to a recent study published in the journal Blood.
Currently, the standard treatment plan involving stem cell transplantation begins with induction therapy, which decreases the number of abnormal cells and proteins in a patient’s bone marrow before collection of stem cells for the transplant. Next, patients undergo high-dose chemotherapy and transplantation, after which, some patients receive consolidation or maintenance therapy.
Past …
Deutsch»

Patienten, die nicht wenigstens partiell auf Revlimid (Lenalidomid) oder Thalidomid vor einer Stammzelltransplantation ansprechen, haben nach einer kürzlich in der Zeitschrift Blood veröffentlichten Studie eine signifikant kürzere Überlebenszeit.
Derzeit beginnt der Standardbehandlungsplan vor einer Stammzelltransplantation mit einer Induktionstherapie, die die Zahl der abnormalen Zellen im Knochenmark des Patienten reduziert, bevor die Stammzellsammlung stattfindet. Dann bekommen die Patienten die Hochdosis-Chemotherapie und Transplantation. Einige Patienten erhalten nach der Transplantation noch eine Konsolidierungs- oder Erhaltungstherapie.
Vorhergehende Studien haben gezeigt, dass unabhängig davon, wie gut der Patient auf die Induktionstherapie anspricht, die Transplantation durchgeführt werden kann …
News»

In its latest version of guidelines for multiple myeloma treatment, the National Comprehensive Cancer Network (NCCN) recommended the use of Revlimid (lenalidomide) as a maintenance therapy after stem cell transplantation. The NCCN based their decision on the preliminary findings of three Phase 3 trials: MM-015, CALGB 100104, and IFM 2005-02.
“[Revlimid] as maintenance has been evaluated in three independent randomized clinical trials. Results from each of these trials show improvements in time-to-progression,” the NCCN myeloma guidelines state. “The panel felt that this warranted inclusion; however, this recommendation remains Category 2A …
News»

A new study published in the British Journal of Haematology suggests that the drug combination regimen of Revlimid (lenalidomide), cyclophosphamide, and prednisone (RCP) is highly effective in multiple myeloma patients who are refractory (not responsive) to Revlimid-dexamethasone (Decadron) treatment.
The researchers of the study had previously shown that continuous low-dose oral cyclophosphamide in combination with prednisone was effective in relapsed multiple myeloma. To further improve the efficacy of the oral regimen, they added Revlimid to the drug combination.
The clinical trial enrolled 14 multiple myeloma patients who …
Deutsch»

Eine neue Studie im British Journal of Haematology legt nahe, dass die Kombinationsbehandlung aus Revlimid (Lenalidomid), Cyclophosphamid und Prednison, abgekürzt RCP, bei Patienten mit multiplen Myelom wirksam ist, bei denen die Behandlung von Revlimid-Dexamethason nicht anschlägt.
Die Autoren der Studie hatten bereits gezeigt, dass kontinuierlich gegebenes niedrig dosiertes Cyclophosphamid mit Prednison bei rezidiviertem Myelom wirksam ist. Um die Wirksamkeit dieser oralen Behandlung zu erhöhen, gaben sie Revlimid dazu.
In Rahmen der klinischen Studie erhielten 14 Patienten mit multiplem Myelom, bei denen die Kombination von Revlimid und Dexamethason nicht anschlug, 10 mg Revlimid …